Mayo neurologist among three to leave panel after Alzheimer s treatment approved for sale 5:30 pm, Jun. 15, 2021 ×
A sign marks a Biogen facility in Cambridge, Mass., Jan. 26, 2017. (REUTERS/Brian Snyder/File Photo)
ROCHESTER, Minn. A Mayo neurologist who recently quit an FDA expert panel in protest has been joined by two others asserting the agency erred in going against experts to approve a new drug for Alzheimer s disease.
In leaving the FDA s Peripheral and Central Nervous System Advisory Committee last week, Mayo Clinic neurologist Dr. David Knopman was joined by Dr. Joel S. Perlmutter, a neurologist at Washington University in St. Louis, and Harvard Medical School ethicist Dr. Aaron Kesselheim.